Lumos Diagnostics receives CPT PLA procedure code approval for FebriDx™ in the US
5 December 2024
Lumos has today announced that it has received approval from the Centers for Medicare and Medicaid Services (CMS) Panel for the FebriDx™ PLA (0442U) code to be reimbursed at a rate of US$41.38/test. The FebriDx PLA code will be published on the Clinical Lab Fee Schedule and take effect January 1,2025.
The PLA code, issued by the American Medical Association, will play a vital role in securing reimbursement for FebriDx from both government and private insurers. This approval is a critical step toward enhancing FebriDx’s accessibility and adoption and is expected to facilitate broader use of the test over time, by making it more affordable.
Lumos Diagnostics Managing Director, Doug Ward, commented:
"This reimbursement pathway is another important step towards removing barriers to access and potentially benefitting millions of Americans.”
Click to read the ASX Release.
The PLA code, issued by the American Medical Association, will play a vital role in securing reimbursement for FebriDx from both government and private insurers. This approval is a critical step toward enhancing FebriDx’s accessibility and adoption and is expected to facilitate broader use of the test over time, by making it more affordable.
Lumos Diagnostics Managing Director, Doug Ward, commented:
"This reimbursement pathway is another important step towards removing barriers to access and potentially benefitting millions of Americans.”
Click to read the ASX Release.
